Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740998 | 1.00 | TRPA1 (0.54) | TRPA1NOS1ROCK2MAPTMETAP2 | |
| Hydrochloric Acid SCHEMBL5419653 | 0.98 | TRPA1 (0.53) | TRPA1NOS1ROCK2MAPTMETAP2 | |
| SCHEMBL578190 | 0.85 | NOS1 (0.53) | NOS1MAPTMETAP2KDM4EMEN1 | |
| SCHEMBL29941668 | 0.85 | NOS1 (0.53) | NOS1MAPTMETAP2KDM4EMEN1 | |
| SCHEMBL5801247 | 0.84 | NOS1 (0.46) | TRPA1NOS1ROCK2MAPTMETAP2 | |
| Hydrochloric Acid SCHEMBL20919850 | 0.83 | NOS1 (0.52) | TRPA1NOS1MAPTMETAP2KDM4E | |
| SCHEMBL3683853 | 0.81 | METAP2 (0.46) | TRPA1METAP2IMPDH2IMPDH1IDO1 | |
| SCHEMBL1413255 | 0.81 | ROCK2 (0.53) | TRPA1NOS1ROCK2MAPTMETAP2 | |
| SCHEMBL1519704 | 0.81 | ROCK2 (0.53) | TRPA1NOS1ROCK2MAPTMETAP2 | |
| Ammonia Solution, Strong SCHEMBL3552635 | 0.80 | PGR (0.49) | TRPA1ROCK2MAOBMAOAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565497-B2 | Sulfone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-03-03 | — | — | US | claimed |
| EP-3924340-B1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| US-20230219953-A1 | SULFONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-13 | — | — | US | claimed |
| CN-115916756-A | Sulfone derivative | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | claimed |
| WO-2007058626-A1 | INDAZOLE COMPOUNDS | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | claimed |
| US-12565497-B2 | Sulfone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-03 | — | — | US | disclosed |
| US-12286406-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
| CN-115605463-B | Inhibitors of receptor-interacting protein kinase I for the treatment of diseases | 德州大学系统董事会 | 2024-08-09 | — | — | CN | disclosed |
| US-4897340-A | RAPIDLY AUTOMATIC PROCESSABLE FILMS HAVING A HYDROPHILIC COLLOIDAL PROTECTIVE LAYER AND A LAYER CONTAINING CORE/SHELL OR TUBULAR GRAINS OF SILVER HALIDE; X-RAY FILMS; WEAR RESISTANCE; ANTISOILANTS | KONICA CORPORATION (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0316864-A2 | Silver halide photographic light-sensitive material and processing method | KONICA CORPORATION (JP) | 1989-05-24 | — | — | EP | disclosed |
| EP-0238271-A2 | Silver halide photographic material and method of processing the same | KONICA CORPORATION (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0060118-B1 | STABLE PHOTOGRAPHIC DEVELOPING SOLUTION CONTAINING AN INDAZOLE ANTIFOGGANT AND A LIGNOSULFONATE | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-02-13 | — | — | EP | disclosed |
| US-4435500-A | AN IMIDAZOLE SOLVENT AND ANTI-FOGGING AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| EP-0060118-A1 | Stable photographic developing solution containing an indazole antifoggant and a lignosulfonate | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4323642-A | Stable photographic developers containing an indazole antifoggant and a lignosulfonate | EASTMAN KODAK COMPANY (US) | 1982-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | TRPA1 3767/4885NOS1 3272/4885ROCK2 640/4885 |
| US-20230219953-A1 | SULFONE DERIVATIVES | SULT1E1, SULT1A1, SULT2A1 | TRPA1 1079/4885NOS1 1414/4885ROCK2 2582/4885 |
| US-12286406-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | TRPA1 3767/4885NOS1 3272/4885ROCK2 640/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | TRPA1 4620/4885NOS1 4766/4885ROCK2 274/4885 |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | TRPA1 4768/4885NOS1 3872/4885ROCK2 852/4885 |
| US-12565497-B2 | Sulfone derivatives | CXCR1, CCR1, SULT1E1 | TRPA1 2310/4885NOS1 2208/4885ROCK2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.